Sequential or alternating administration of docetaxel (Taxotere®) combined with FEC in metastatic breast cancer: a randomised phase II trial

The aim of this study, using a Fleming single-stage design, was to explore the efficacy and safety of Taxotere® 100 mg m(−2) docetaxel and FEC 75 cyclophosphamide 500 mg m(−2), fluorouracil 500 mg m(−2) and epirubicin 75 mg m(−2), in alternating and sequential schedules for the first-line treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Spielmann, M, Tubiana-Hulin, M, Namer, M, Mansouri, H, Bougnoux, P h, Tubiana-Mathieu, N, Lotz, V, Eymard, J C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375306/
https://www.ncbi.nlm.nih.gov/pubmed/11875727
http://dx.doi.org/10.1038/sj.bjc.6600165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375306/
https://www.ncbi.nlm.nih.gov/pubmed/11875727
http://dx.doi.org/10.1038/sj.bjc.6600165

Ejemplares similares